Can Stem-Cell implants restore movement in Parkinson's?
NCT ID NCT07733349
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether implanting dopamine-producing cells into the brain can improve motor function in people with Parkinson's disease. The cells, made from stem cells, are surgically placed into the putamen. The study focuses on safety and whether the treatment can reduce symptoms like stiffness and tremors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- implanted dopamine-producing cells made from stem cells
- What this could lead to
- If it works, this could point toward a cell-replacement therapy that restores dopamine production and improves motor symptoms in Parkinson's disease.
- What could go wrong
- This is an early-phase trial with only 12 participants, so safety and effectiveness are not yet established. The surgical implantation carries risks such as bleeding, infection, or immune rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged between 30 and 75 years, regardless of gender * Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years * Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined * Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30% * The modified H\&Y staging (Off period) of ≥2.5 and ≤4, with total daily "off" time \>2 hours * Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening * Good physical condition or stable concomitant diseases Exclusion Criteria: * The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome * Severe systemic diseases or functional impairments * Evidence of active infection or chronic infection, which may pose a risk to the subject * Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders * Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT/MRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks * Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months * Subjects with a history of severe allergies or hypersensitivity reactions, known hypersensitivity to the investigational drug or its ancillary materials, or intolerance to them * Pregnant or breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking memory tests may reveal early Parkinson's clues
- Colon tissue may hold clues to telling Parkinson's apart from Look-Alike diseases
- A genetic roadmap for Parkinson's: testing thousands to unlock clues
- Can gentle touch therapy calm Parkinson's tremors?
- Stem cell infusions aim to slow Parkinson's progression
- Can an inhaled levodopa ease Parkinson's OFF episodes? a study asks patients.